10.6084/m9.figshare.11966100.v1
Fabio Mendonça Xavier Andrade
Fabio Mendonça Xavier
Andrade
Fabiola Rosa Picosse
Fabiola Rosa
Picosse
Laura Pires da Cunha
Laura Pires da
Cunha
Camila Maia Valente
Camila Maia
Valente
Fernanda Machado Bezerra
Fernanda Machado
Bezerra
Helio Miot
Helio
Miot
Edileia Bagatin
Edileia
Bagatin
Denise de Freitas
Denise de
Freitas
Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline
SciELO journals
2020
Rosacea/drug therapy
Doxycycline/therapeutic use
Doxycycline/administration & dosage
Isotretinoin/the rapeutic use
Isotretinoin/administration & dosage
Ocular sur face
Blepharitis
2020-03-11 02:45:31
Dataset
https://scielo.figshare.com/articles/dataset/Ocular_surface_changes_in_the_treatment_of_rosacea_comparison_between_low-dose_oral_isotretinoin_and_doxycycline/11966100
<div><p>ABSTRACT Purpose: To compare the impact of ocular changes between systemic treatment with doxycycline and low-dose oral isotretinoin in patients with moderate-to-severe papulopustular rosacea. Methods: Patients were randomized to receive either isotretinoin 0.3-0.4 mg/kg (group A) or doxycycline 100 mg/day (group B) for 16 weeks. Ocular symptoms were searched and evaluated, including best-corrected visual acuity (BCVA), Schirmer test, breakup time, rose bengal staining score, and meibomian gland dysfunction grading. The patients were retested at the end of treatment. Results: The present study included 39 patients (30 females and 9 males). Best-corrected visual acuity was > 20/30 in >90% of patients in both groups and did not change after treatment. After treatment, improvement in ocular symptoms and meibomian gland dysfunction was more pronounced in group B (p<0.05); the other parameters did not reach statistical significance. Conclusion: Doxycycline improved meibomian gland dysfunction, ocular symptoms, and ocular surface in patients with rosacea. Even though some patients experienced worsening meibomian gland dysfunction and symptoms, no subject experienced any serious complications after administration of low-dose isotretinoin.</p></div>